Targeting glucocorticoid receptor signaling in platinum-resistant ovarian cancer: translational rationale and clinical advances following the ROSELLA trial
{{output}}
Platinum-resistant ovarian cancer (PROC) remains a major clinical challenge, with limited effective treatment options and poor survival outcomes. Aberrant activation of the glucocorticoid receptor (GR) signaling pathway promotes tumor progression, chemoresista... ...
